A Multi-Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C.

Trial Profile

A Multi-Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Albinterferon alfa 2B (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 27 Apr 2011 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov.
    • 27 Apr 2011 Actual initiation date (1 Oct 2004) added as reported by ClinicalTrials.gov.
    • 01 Nov 2007 Final results will be presented at AASLD in November 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top